A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Phase 2 Completed 36 enrolled AstraZeneca Analytical Laboratory (Pharmacokinetic Sample Analysis): USA · collab Clinical Laboratory: USA · collab Contract Research Organization: USA · collab Covance Bioanalytical Services, LLC · collab GenX Laboratories Inc. · collab Harbor Hospital Laboratory · collab PAREXEL Early Phase Clinical Unit Baltimore · collab PAREXEL Early Phase Clinical Unit-Los Angeles · collab

RandomizedCrossoverDouble-blindTreatment

Summary

This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat + dapagliflozin/placebo) and follow-up visit

Timeline

Start: 2017-10-25
Primary completion: 2018-07-19
Completion: 2018-07-19

Publications

Stack AG, Han D, Goldwater R, Johansson S, Dronamraju N, Oscarsson J, Johnsson E, Parkinson J, Erlandsson F. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study. J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2347-e2356. doi: 10.1210/clinem/dgaa748.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral
Background	Febuxostat	Small molecule	80 mg	Oral
Background	Verinurad	Small molecule	9 mg	Oral

Indications

No indication recorded.